Abbvie Inc

NYSE:ABBV   2:58:43 PM EDT
134.26
+2.10 (+1.59%)
Other Pre-Announcement

Abbvie Confirms Guidance Of Greater Than $15 Billion In Combined Risk-Adjusted Sales For Rinvoq And Skyrizi In 2025

Published: 01/11/2022 14:04 GMT
Abbvie Inc (ABBV) - Abbvie Confirms Guidance of Greater Than $15 Billion in Combined Risk-adjusted Sales for Rinvoq and Skyrizi in 2025.
Abbvie Inc - New Rinvoq Sales Guidance is Result of Lower Expected Rinvoq Sales in U.S. Following Recent Label Updates.
Abbvie Inc - Now Expects 2025 Risk-adjusted Sales of Greater Than $7.5 Billion for Rinvoq and Greater Than $7.5 Billion for Skyrizi.
Abbvie Inc - Updated Skyrizi Sales Guidance is Based on Continued Strong Performance in Psoriasis.